Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a pivotal Phase III trial of zemprocitinib...
Lynk Pharmaceuticals Co., Ltd. and Formation Bio announced that Bleecker Bio, a newly formed Formation...
Lynk Pharmaceuticals Co., Ltd. announced that its self‑developed TYK2 allosteric inhibitor LNK01006 has received FDA...
Lynk Pharmaceuticals Co., Ltd. announced positive Phase II data for its self‑developed Class 1 innovative drug LNK01004,...
Lynk Pharmaceuticals Co., Ltd, based in China, has announced the dosing of the first patient...
China-based Lynk Pharmaceuticals Co., Ltd has announced that the first patient has been dosed in...
Lynk Pharmaceuticals Co., Ltd, a China-based pharmaceutical company, has announced the successful completion of its...
China-based Lynk Pharmaceuticals Co., Ltd has announced positive topline results from the Phase II clinical...
China-based Lynk Pharmaceuticals Co., Ltd has announced that its Phase II clinical study for LNK01001...
China-based Lynk Pharmaceuticals Co., Ltd has successfully raised RMB 200 million (USD 28.3 million) through...
China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of...
US-based biotech EQRx Inc., (Nasdaq: EQRX) has disclosed in its Q4 2022 financial report a...
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd has announced the successful conclusion of a Phase I...
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...
Hangzhou-based Lynk Pharmaceuticals Co., Ltd announced it has received approval from the National Medical Products...